TYME Key Statistics, Chart & Performance
The current stock price of TYME is 0.3107 USD. In the past month the price decreased by -2.97%. In the past year, price decreased by -69.84%.
TYME Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TYME. When comparing the yearly performance of all stocks, TYME is a bad performer in the overall market: 73.6% of all stocks are doing better.
TYME Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TYME. The financial health of TYME is average, but there are quite some concerns on its profitability.
TYME Financial Highlights
Over the last trailing twelve months TYME reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS increased by 22.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.18% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
TYME Forecast & Estimates
7 analysts have analysed TYME and the average price target is 9.69 USD. This implies a price increase of 3018.76% is expected in the next year compared to the current price of 0.3107.
TYME Ownership
TYME Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About TYME
Company Profile
Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. The company is headquartered in Bedminster, New Jersey and currently employs 13 full-time employees. The company went IPO on 2012-05-25. TYME's lead drug product, SM-88, is an oral investigational modified proprietary tyrosine derivative that interrupt the metabolic processes of cancer cells by breaking down the cells key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. TYME is focused on evaluating its preclinical pipeline of novel CMBT programs, and TYME-19 as a potential therapeutic for SARS CoV-2 diseases. Its preclinical pipeline programs SM-88i, TYME-18, TYME-T and TYME-19. The firm is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications and TYME-18 for the treatment of solid tumors. The firm is utilizing its metabolism-based technology and is developing TYME-19 as a potential therapeutic for coronavirus, the virus that causes Covid-19.
Company Info
TYME TECHNOLOGIES INC
1 Pluckemin Way - Suite 103
Bedminster NEW JERSEY 07921 US
CEO: Richard Cunningham
Employees: 13
Phone: 12124612315.0
TYME TECHNOLOGIES INC / TYME FAQ
Can you describe the business of TYME TECHNOLOGIES INC?
Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. The company is headquartered in Bedminster, New Jersey and currently employs 13 full-time employees. The company went IPO on 2012-05-25. TYME's lead drug product, SM-88, is an oral investigational modified proprietary tyrosine derivative that interrupt the metabolic processes of cancer cells by breaking down the cells key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. TYME is focused on evaluating its preclinical pipeline of novel CMBT programs, and TYME-19 as a potential therapeutic for SARS CoV-2 diseases. Its preclinical pipeline programs SM-88i, TYME-18, TYME-T and TYME-19. The firm is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications and TYME-18 for the treatment of solid tumors. The firm is utilizing its metabolism-based technology and is developing TYME-19 as a potential therapeutic for coronavirus, the virus that causes Covid-19.
Can you provide the latest stock price for TYME TECHNOLOGIES INC?
The current stock price of TYME is 0.3107 USD. The price increased by 8.07% in the last trading session.
What is the dividend status of TYME TECHNOLOGIES INC?
TYME does not pay a dividend.
What is the ChartMill technical and fundamental rating of TYME stock?
TYME has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is TYME stock listed?
TYME stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for TYME TECHNOLOGIES INC?
TYME TECHNOLOGIES INC (TYME) operates in the Health Care sector and the Biotechnology industry.